Lanton is government affairs director for the American Association of Clinical Urology.
Biomarkers in urology: Policy and legislative advances
"The AACU has been discussing the evolution of state policy to ensure that biomarker testing, including PSA screening, is covered by payers," writes Ron Lanton, Esq.
CHAI biomarkers demonstrate prognostic utility for high-grade Ta NMIBC
Is there a difference between MD and DO in urology?
64Cu-SAR-Bombesin shows efficacy in detecting prostate cancer recurrence
From prep to follow-up: Key considerations for administering onabotulinumtoxinA